Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics | Zendy

Wendy Ankrom | Zendy; Ka Lai Yee | Zendy; Rosa I. Sánchez | Zendy; Adedayo Adedoyin | Zendy; Fan Li | Zendy; Thomas Marbury | Zendy; Richard A. Preston | Zendy; Marian Iwamoto | Zendy; Sauzanne Khalilieh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

Author(s) -

Wendy Ankrom,

Ka Lai Yee,

Rosa I. Sánchez,

Adedayo Adedoyin,

Fan Li,

Thomas Marbury,

Richard A. Preston,

Marian Iwamoto,

Sauzanne Khalilieh

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00326-18

Subject(s) - reverse transcriptase inhibitor , pharmacokinetics , cytochrome p450 , pharmacology , human immunodeficiency virus (hiv) , medicine , virology , sida , viral disease , metabolism

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor in development for use with other antiretroviral therapies to treat human immunodeficiency virus type 1 (HIV-1) infection. Doravirine metabolism predominantly occurs via cytochrome P450 3A with <10% of elimination occurring via the renal pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research